Developing and assessing cardiovascular biomarkers

Translational Research

Volumn 159, Issue 4, 2012, Pages 265-276

  Dadu, Razvan T ^a   Nambi, Vijay ^a   Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CANAKINUMAB; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; ROSUVASTATIN; TROPONIN T;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; FOLLOW UP; FRAMINGHAM RISK SCORE; GENETIC RISK; HAZARD RATIO; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; METABOLIC SYNDROME X; MORTALITY; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REPRODUCIBILITY; REVIEW; REYNOLDS RISK SCORE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84858403662     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.01.003     Document Type: Review

References (106)

1. J.C. Tardif, T. Heinonen, and D. Orloff Vascular biomarkers and surrogates in cardiovascular disease Circulation 113 2006 2936 2942
2. V. Nambi, and C.M. Ballantyne Role of biomarkers in developing new therapies for vascular disease World J Surg 31 2007 676 681
3. J. LaBaer So, you want to look for biomarkers J Proteome Res 4 2005 1053 1059
4. R.S. Vasan Biomarkers of cardiovascular disease: molecular basis and practical considerations Circulation 113 2006 2335 2362
5. M.A. Hlatky Exercise testing to predict outcome in patients with angina J Gen Intern Med 14 1999 63 65
6. E. von Elm, D.G. Altman, M. Egger STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Ann Intern Med 147 2007 573 577
7. M.A. Hlatky, P. Greenland, and D.K. Arnett Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 2408 2416
8. M.J. Pencina, RB Sr D'Agostino, and R.B. D'Agostino Jr. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 30 27 2008 199 206
9. R.N. Cook Statistical evaluation of prognostic vs diagnostic models: beyond the ROC curve Clin Chem 54 2008 117 123
10. R.A. Temple regulatory authority's opinion about surrogate endpoints W.S. Nimmo, G.T. Tucker, Clinical measurement in drug evaluation 1995 Wiley New York, NY 3 22
11. S.S. Bassuk, N. Rifai, and P.M. Ridker High-sensitivity C-reactive protein: clinical importance Curr Probl Cardiol 29 2004 439 493
12. V. Pasceri, J.T. Willerson, and E.T. Yeh Direct proinflammatory effect of C-reactive protein on human endothelial cells Circulation 102 2000 2165 2168
13. V. Pasceri, J.S. Cheng, and J.T. Willerson Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs Circulation 103 2001 2531 2534
14. S. Verma, S.H. Li, and M.V. Badiwala Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein Circulation 105 2002 1890 1896
15. S. Devaraj, D.Y. Xu, and I. Jialal C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis Circulation 107 2003 398 404
16. S.K. Venugopal, S. Devaraj, and I. Yuhanna Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells Circulation 106 2002 1439 1441
17. S. Verma, C.H. Wang, and S.H. Li A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis Circulation 106 2002 913 919
18. T.P. Zwaka, V. Hombach, and J. Torzewski C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis Circulation 103 2001 1194 1197
19. P. Libby, P.M. Ridker, and A. Maseri Inflammation and atherosclerosis Circulation 105 2002 1135 1143
20. P.M. Ridker, C.H. Hennekens, and J.E. Buring C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843
21. P.M. Ridker, M. Cushman, and M.J. Stampfer Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
22. P.M. Ridker C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease Clin Chem 55 2009 209 215
23. P.M. Ridker, N. Rifai, M.A. Pfeffer Cholesterol and Recurrent Events (CARE) Investigators Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels Circulation 98 1998 839 844
24. P.M. Ridker, N. Rifai, and M. Clearfield Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
25. P.M. Ridker, E. Danielson, F.A.H. Fonseca JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
26. E.Y. Yang, V. Nambi, and Z. Tang Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study J Am Coll Cardiol 54 2009 2388 2395
27. M. Tohidi, F. Hadaegh, and H. Harati C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study Int J Cardiol 132 2009 369 374
28. R. Arena, J.A. Arrowood, and D.Y. Fei The relationship between C-reactive protein and other cardiovascular risk factors in men and women J Cardiopulm Rehabil 26 2006 323 327
29. M. Raitakari, K. Mansikkaniemi, and J. Marniemi Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: the Cardiovascular Risk in Young Finns Study J Intern Med 258 2005 428 434
30. M.J. Williams, S.M. Williams, and B.J. Milne Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults Int J Obes Relat Metab Disord 28 2004 998 1003
31. S. Kaptoge, E. Di Angelantonio, G. Lowe Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
32. P.M. Ridker, J.E. Buring, and N. Rifai Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 297 2007 611 619
33. T.J. Wang, G. Martin, and G.M. Larson C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study Circulation 106 2002 1189 1191
34. R.F. Redberg, N. Rifai, L. Gee, and P.M. Ridker Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening J Am Coll Cardiol 36 2000 39 43
35. M.W. Lorenz, P. Karbstein, H.S. Markus, and M. Sitzer High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the Carotid Atherosclerosis Progression Study Stroke 38 2007 1774 1779
36. S. Makita, M. Nakamura, and K. Hiramori The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population Stroke 36 2005 2138 2142
37. A.R. Folsom, L.E. Chambless, and C.M. Ballantyne An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities study Arch Intern Med 166 2006 1368 1373
38. P.M. Ridker, N. Rifai, and L. Rose Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
39. W. Koenig, H. Löwel, J. Baumert, and C. Meisinger C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany Circulation 109 2004 1349 1353
40. P. Greenland, J.S. Alpert, and G.A. Beller 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 2010 2182 2199
41. U.S. Preventive Services Task Force Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 151 2009 474 482
42. A. Dehghan, J. Dupuis, and M. Barbalic Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels Circulation 123 2011 731 738
43. P. Elliott, J.C. Chambers, and W. Zhang Genetic loci associated with C-reactive protein levels and risk of coronary heart disease JAMA 302 2009 37 48
44. P.M. Ridker, T. Thuren, A. Zalewski, and P. Libby Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 162 2011 597 605
45. S. Bhatti, A. Hakeem, and M. Cilingiroglu Lp-PLA2 as a marker of cardiovascular diseases Curr Atheroscler Rep 12 2010 140 144
46. C. Iribarren Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions Arterioscler Thromb Vasc Biol 26 2006 5 6
47. 2), a novel marker of cardiovascular risk Circulation 110 Suppl III 2004 III-309
48. 2 Clin Lab Med 26 2006 679 697
49. C.J. Packard, D.S. O'Reilly, M.J. Caslake West of Scotland Coronary Prevention Study Group Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease N Engl J Med 343 2000 1148 1155
50. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study Circulation 109 2004 837 842
51. C.A. Garza, V.M. Montori, and J.P. McConnel Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review Mayo Clin Proc 82 2007 159 165
52. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany Circulation 110 2004 1903 1908
53. H.H. Oei, I.M. van der Meer, and A. Hofman Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study Circulation 111 2005 570 575
54. J.S. Rana, M. Cote, and J.P. Despres Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk Prospective Population Study Heart 95 2009 1682 1687
55. V. Nambi, R.C. Hoogeveen, L. Chambless, and Y. Hu Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study Stroke 40 2009 376 381
56. M. Persson, B. Hedblad, and J.J. Nelson Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects Arterioscler Thromb Vasc Biol 27 2007 1411 1416
57. K. Winkler, M.M. Hoffmann, and B.R. Winkelmann Lipoprotein-associated phospholipase A2 predicts 5-year mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study) Clin Chem 53 2007 1440 1447
58. Y. Gerber, J.P. McConnell, A.S. Jaffe, S.A. Weston, J.M. Killian, and V.L. Roger Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community Arterioscler Thromb Vasc Biol 26 2006 2517 2522
59. M. Mockel, R. Muller, and J.O. Vollert Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach. The North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II) Clin Res Cardiol 96 2007 604 612
60. M.A. Corson, P.H. Jones, and M. Davidson Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker Am J Cardiol 101 2008 41F 50F
61. S. Suchindran, D. Rivedal, and J.R. Guyton Genome-wide association study of Lp-PLA2 activity and mass in the Framingham Heart Study PLoS Genet 4 2010 e1000928
62. H. Grallert, J. Dupuis, and J.C. Bis Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies Eur Heart J 33 2012 238 251
63. C.H. MacPhee Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target Curr Opin Pharmacol 1 2001 121 125
64. 2: 1- (biphenylmethylamidoalkyl)-pyrimidones Bioorg Med Chem Lett 12 2002 51 55
65. 2 inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 2008 1172 1182
66. G.G. Schwartz, A.G. Olsson, and C.M. Ballantyne Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome Am Heart J 158 2009 896 901.e3
67. W. Hochholzer, D.A. Morrow, and R.P. Giugliano Novel biomarkers in cardiovascular disease: update 2010 Am Heart J 160 2010 583 594
68. E.A. Podrez, D. Schmitt, and H.F. Hoff Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro J Clin Invest 103 1999 1547 1560
69. T. Naruko, M. Ueda, and K. Haze Neutrophil infiltration of culprit lesions in acute coronary syndromes Circulation 106 2002 2894 2900
70. A. Buffon, L.M. Biasucci, and G. Liuzzo Widespread coronary inflammation in unstable angina N Engl J Med 347 2002 5 12
71. S. Sugiyama, Y. Okada, and J.K. Sukhova Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes Am J Pathol 158 2001 879 891
72. R. Zhang, M.L. Brennan, and X. Fu Association between myeloperoxidase levels and risk of coronary artery disease JAMA 286 2001 2136 2142
73. M.C. Meuwese, E.S. Stroes, and S.L. Hazen Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study J Am Coll Cardiol 50 2007 159 165
74. S. Baldus, C. Heeschen, and T. Meinertz Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes Circulation 208 2003 1440 1445
75. M.L. Brennan, M.S. Penn, and F.V. Lente Prognostic value of myeloperoxidase in patients with chest pain N Engl J Med 209 2003 1595 1604
76. C.L. Heslop, J.L. Frohlich, and J.S. Hill Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography J Am Coll Cardiol 55 2010 1102 1109
77. C.K. Roberts, D. Won, and S. Pruthi Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors J Appl Physiol 100 2006 1657 1665
78. H.A. Katus, A. Remppis, and T. Scheffold Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction Am J Cardiol 67 1991 1360 1367
79. V. Ricchiuti, E.M. Voss, and A. Ney Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim Clin Chem 44 1998 1919 1924
80. K. Thygesen, J.S. Alpert, and H.D. White Universal definition of myocardial infarction Circulation 116 2007 2634 2653
81. T.W. Wallace, S.M. Abdullah, and M.H. Drazner Prevalence and determinants of troponin T elevation in the general population Circulation 113 2006 1958 1965
82. B. Lindahl, P. Venge, and L. Wallentin Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease Circulation 93 1996 1651 1657
83. L.B. Daniels, G.A. Laughlin, and P. Clopton Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study J Am Coll Cardiol 52 2008 450 459
84. K.M. Eggers, B. Lagerqvist, and P. Venge Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality Circulation 116 2007 1907 1914
85. R. Latini, S. Masson, and I.S. Anand Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure Circulation 116 2007 1242 1249
86. T. Omland, J.A. de Lemos, and M.S. Sabatine A sensitive cardiac troponin T assay in stable coronary artery disease N Engl J Med 361 2009 2538 2547
87. J.A. de Lemos, M.H. Drazner, and T. Omland Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population JAMA 304 2010 2503 2512
88. C.R. deFilippi, J.A. de Lemos, and R.H. Christenson Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults JAMA 304 2010 2494 2502
89. J.T. Saunders, V. Nambi, and J.A. de Lemos Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study Circulation 123 2011 1367 1376
90. H. Yasue, M. Yoshimura, and H. Sumida Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure Circulation 90 1994 195 203
91. B.C. Stein, and R.I. Levin Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease Am Heart J 135 1998 914 923
92. T. Omland, A. Aakvaag, and H. Vik-Mo Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment Heart 76 1996 232 237
93. E.R. Levin, D.G. Gardner, and W.K. Samson Natriuretic peptides N Engl J Med 339 1998 321 328
94. L.B. Daniels, and A.S. Maisel Natriuretic peptides J Am Coll Cardiol 50 2007 2357 2368
95. D.A. Morrow, C.P. Cannon, R.L. Jesse NACB Writing Group National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes Circulation 115 2007 e356 e375
96. A.L. Ribeiro Natriuretic peptides in elderly people with acute myocardial infarction BMJ 338 2009 b787
97. T. Omland, M.S. Sabatine, and K.A. Jablonski Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial J Am Coll Cardiol 50 2007 205 214
98. T.J. Wang, M.G. Larson, and D. Levy Plasma natriuretic peptide levels and the risk of cardiovascular events and death N Engl J Med 350 2004 655 663
99. J.A. de Lemos, D.A. Morrow, and J.H. Bentley The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes N Engl J Med 345 2001 1014 1021
100. E.D. Angelantonio, R. Chowdhury, and N. Sarwar B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies Circulation 120 2009 2177 2187
101. P.M. McKie, R.J. Rodeheffer, and A. Cataliotti Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure Hypertension 47 2006 874 880
102. M.H. Olsen, T.W. Hansen, and M.K. Christensen Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex J Hypertens 26 2008 26 34
103. C. Kistorp, I. Raymond, and F. Pedersen N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults JAMA 293 2005 1609 1616
104. T.A. McDonagh, A.D. Cunningham, and C.E. Morrison Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population Heart 86 2001 21 26
105. J.A. Laukkanen, S. Kurl, and M. Ala-Kopsala Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men Eur Heart J 27 2006 1230 1237
106. S. Blankenberg, M.J. McQueen, and M. Smieja Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study Circulation 114 2006 201 208